Literature DB >> 26968700

Bioenergetics and metabolism: a bench to bedside perspective.

Russell H Swerdlow1.   

Abstract

'Metabolism' refers to the vast collection of chemical processes that occur within a living organism. Within this broad designation, one can identify metabolism events that relate specifically to energy homeostasis, whether they occur at the subcellular, cellular, organ, or whole organism level. This review operationally refers to this type of metabolism as 'energy metabolism' or 'bioenergetics.' Changes in energy metabolism/bioenergetics have been linked to brain aging and a number of neurodegenerative diseases, and research suggests mitochondria may uniquely contribute to this. Interventions that manipulate energy metabolism/bioenergetic function and mitochondria may have therapeutic potential and efforts intended to accomplish this are playing out at basic, translational, and clinical levels. This review follows evolving views of energy metabolism's role in neurodegenerative diseases but especially Alzheimer's disease, with an emphasis on the bench-to-bedside process whose ultimate goal is to develop therapeutic interventions. It further considers challenges encountered during this process, which include linking basic concepts to a medical question at the initial research stage, adapting conceptual knowledge gained to a disease-associated application in the translational stage, extending what has been learned to the clinical arena, and maintaining support for the research at each of these fundamentally linked but functionally distinct stages. A bench-to-bedside biomedical research process is discussed that moves through conceptual, basic, translational, and clinical levels. For example, herein a case was made that bioenergetics is a valid Alzheimer's disease therapeutic target. Following this, a fundamental strategy for manipulating bioenergetics was defined, potential implications studied, and the approach extended to the clinical arena. This article is part of the 60th Anniversary special issue.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  Alzheimer's disease; bioenergetics; metabolism; mitochondria; neurodegeneration

Mesh:

Year:  2016        PMID: 26968700      PMCID: PMC5851778          DOI: 10.1111/jnc.13509

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  117 in total

1.  The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.

Authors:  Camilla A Hansson Petersen; Nyosha Alikhani; Homira Behbahani; Birgitta Wiehager; Pavel F Pavlov; Irina Alafuzoff; Ville Leinonen; Akira Ito; Bengt Winblad; Elzbieta Glaser; Maria Ankarcrona
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

2.  Mitochondrial function in Parkinson's disease.

Authors:  L A Bindoff; M Birch-Machin; N E Cartlidge; W D Parker; D M Turnbull
Journal:  Lancet       Date:  1989-07-01       Impact factor: 79.321

3.  Nucleoside phosphatase activities associated with the tangles and plaques of alzheimer's disease: a histochemical study of natural and experimental neurofibrillary tangles.

Authors:  A B Johnson; N R Blum
Journal:  J Neuropathol Exp Neurol       Date:  1970-07       Impact factor: 3.685

4.  Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance.

Authors:  Anna Wredenberg; Christoph Freyer; Marie E Sandström; Abram Katz; Rolf Wibom; Håkan Westerblad; Nils-Göran Larsson
Journal:  Biochem Biophys Res Commun       Date:  2006-09-18       Impact factor: 3.575

5.  Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

Authors:  A Bender; W Koch; M Elstner; Y Schombacher; J Bender; M Moeschl; F Gekeler; B Müller-Myhsok; T Gasser; K Tatsch; T Klopstock
Journal:  Neurology       Date:  2006-10-10       Impact factor: 9.910

Review 6.  Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-09-15       Impact factor: 8.401

7.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

Review 8.  Coenzyme Q10 in neuromuscular and neurodegenerative disorders.

Authors:  M Mancuso; D Orsucci; L Volpi; V Calsolaro; G Siciliano
Journal:  Curr Drug Targets       Date:  2010-01       Impact factor: 3.465

9.  PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.

Authors:  Weiping Qin; Vahram Haroutunian; Pavel Katsel; Christopher P Cardozo; Lap Ho; Joseph D Buxbaum; Giulio M Pasinetti
Journal:  Arch Neurol       Date:  2009-03

10.  Mitochondrial genetics: a paradigm for aging and degenerative diseases?

Authors:  D C Wallace
Journal:  Science       Date:  1992-05-01       Impact factor: 47.728

View more
  15 in total

1.  Measurement of Mitochondrial Respiration in Platelets.

Authors:  Zdeněk Fišar; Jana Hroudová
Journal:  Methods Mol Biol       Date:  2021

2.  Assessment of the Effects of Drugs on Mitochondrial Respiration.

Authors:  Jana Hroudová; Zdeněk Fišar
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.

Authors:  Judit M Perez Ortiz; Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

Review 4.  Molecular and cellular aspects of age-related cognitive decline and Alzheimer's disease.

Authors:  Rikki Hullinger; Luigi Puglielli
Journal:  Behav Brain Res       Date:  2016-05-07       Impact factor: 3.332

Review 5.  Relationship Between β-Amyloid and Mitochondrial Dynamics.

Authors:  Dah Ihm Kim; Ki Hoon Lee; Ji Young Oh; Jun Sung Kim; Ho Jae Han
Journal:  Cell Mol Neurobiol       Date:  2016-10-20       Impact factor: 5.046

6.  Metabolomic Assays of Postmortem Brain Extracts: Pitfalls in Extrapolation of Concentrations of Glucose and Amino Acids to Metabolic Dysregulation In Vivo in Neurological Diseases.

Authors:  Gerald A Dienel
Journal:  Neurochem Res       Date:  2018-08-16       Impact factor: 3.996

7.  Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses.

Authors:  Anatoliy I Yashin; Fang Fang; Mikhail Kovtun; Deqing Wu; Matt Duan; Konstantin Arbeev; Igor Akushevich; Alexander Kulminski; Irina Culminskaya; Ilya Zhbannikov; Arseniy Yashkin; Eric Stallard; Svetlana Ukraintseva
Journal:  Exp Gerontol       Date:  2017-10-26       Impact factor: 4.032

Review 8.  Mitochondria and Mitochondrial Cascades in Alzheimer's Disease.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.

Authors:  Eric D Vidoni; In-Young Choi; Phil Lee; Gregory Reed; Na Zhang; Joseph Pleen; Jonathan D Mahnken; Jonathan Clutton; Annette Becker; Erica Sherry; Rebecca Bothwell; Heidi Anderson; Robert A Harris; William Brooks; Heather M Wilkins; Lisa Mosconi; Jeffrey M Burns; Russell H Swerdlow
Journal:  Alzheimers Dement       Date:  2020-07-27       Impact factor: 21.566

10.  Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and cortex.

Authors:  Sirui Jiang; Priya Nandy; Wenzhang Wang; Xiaopin Ma; Jeffrey Hsia; Chunyu Wang; Zhenlian Wang; Mengyue Niu; Sandra L Siedlak; Sandy Torres; Hisashi Fujioka; Ying Xu; Hyoung-Gon Lee; George Perry; Jun Liu; Xiongwei Zhu
Journal:  Mol Neurodegener       Date:  2018-02-01       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.